Probe • Vol LXII • No. 3 • May–Aug 2023 • 5 Liv.52 DS in the Management of Nonalcoholic Steatohepatitis study period. Significant changes in the USG findings and NAFLD scores were also noticed (Tables 2 and 3). No adverse reactions were observed or reported during the study. Conclusion The results show that treating patients with NASH with Liv.52 DS tablet for 3 months improved their clinical and liver function parameters, USG findings, and NAFLD scores. Thus, Liv.52 DS tablet is effective and safe in the management of NASH. Summary • Fifty patients (of both sexes) suffering from steatohepatitis were enrolled into this study. • The patients were advised to take 2 Liv.52 DS tablets, BID, for 3 months. • Systemic examination, hematologic and liver function tests, ultrasonography (USG), and a noninvasive NAFLD scoring were performed at monthly intervals. • Improvements in liver function parameters after the administration of Liv.52 DS tablets and incidence of adverse events and overall compliance to the therapy were considered as the primary and the secondary end points, respectively. • Significant improvements in abdominal discomfort due to hepatomegaly, fatigue, weakness, body weight, and recurrent infections were observed. • Gradual improvements in the hematological and biochemical parameters were also observed. • Significant improvements in the USG findings and NAFLD scores were also noticed. • The study results confirm the safety and efficacy of Liv.52 DS tablet in the management of NASH. Sources: Das JKL, et al. Med Update. 2007;15(7):31–36. Ghosh S, et al. Int J Curr Res Aca Rev. 2014;2(9):1–12. Table 1. Effect of Liv.52 DS on Clinical Parameters Parameter Screening Month 1 Month 3 Abdominal Discomfort Due to Hepatomegaly 0.62 ± 0.67 2.38 ± 0.67a 4.62 ± 0.49a,b Fatigue 0.68 ± 1.52 2.62 ± 0.92a 4.74 ± 0.44a,b Weakness 0.44 ± 0.58 2.54 ± 0.54a 4.80 ± 0.40a,b Weight Loss 3.20 ± 2.42 3.96 ± 1.44 4.60 ± 0.61c Recurrent Infections 4.32 ± 1.17 4.76 ± 0.48 5.00 ± 0.00d Statistical test: Friedman test followed by Dunn’s multiple comparisons test. aP < .001; bP < .001; cP < .01; and dP < .05 compared with at-entry values. Table 2. Effect of Liv.52 DS Based on USG Findings (Mean ± SD) Before the Treatment After the Treatment Significance 1.58 ± 0.64 0.66 ± 0.56 P < .0001 USG, ultrasonography. Table 3. Effect of Liv.52 DS on NAFLD Score At Entry End of the Study − 0.98 ± 0.39 − 1.22 ± 0.41 NAFLD score interpretation: < − 1.455 = F0-F2; − 1.455 to 0.675 = indeterminate score; and > 0.675 = F3-F4. NAFLD, nonalcoholic fatty liver disease.
RkJQdWJsaXNoZXIy MjAwNDg=